Form 4: Crinetics Pharmaceuticals CFO Marc Wilson Executes Stock Option and Sells Shares

Crinetics Pharmaceuticals CFO Marc Wilson exercised stock options and sold 25,000 shares of common stock on September 26, 2024, according to a Form 4 filing.

Summary

• On September 26, 2024, Marc Wilson, CFO of Crinetics Pharmaceuticals, exercised a stock option to acquire 25,000 shares of common stock at a price of $15.29 per share.
• Simultaneously, Wilson sold 25,000 shares of Crinetics Pharmaceuticals common stock in open market transactions at a volume weighted average price of $51.11 per share.
• The sales prices ranged from $50.28 to $51.54 per share on the transaction date.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Wilson directly owns 111,092 shares of Crinetics Pharmaceuticals common stock.
• Wilson also holds options to purchase 89,000 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as insider sales can sometimes be interpreted negatively, although sales under a 10b5-1 plan are generally viewed as less concerning.

Key Dates